Patient Aid for Theory-Driven Health Communication (PATH): Translating Goal-Power Theory Into an Instrument and Generative AI Support for Palliative Care Communication
The goal of this clinical trial is to learn whether an artificial intelligence (AI)-supported communication tool can help improve communication between people receiving palliative care and their healthcare providers. The study will also evaluate a new questionnaire designed to measure the quality of healthcare communication.
The main questions this study aims to answer are:
- Can the new questionnaire accurately measure the quality of communication between participants and healthcare providers?
- Does using the AI-supported communication tool, called NurseChat+, help participants feel more confident and prepared before meeting with their healthcare team?
- Does NurseChat+ improve the quality of communication during palliative care visits?
Researchers will compare participants who use NurseChat+ together with their usual care to participants who receive usual care alone to see whether the tool improves communication outcomes.
The study will be conducted in three stages. First, researchers will develop and test a questionnaire that measures healthcare communication. Next, they will develop and refine the NurseChat+ tool. Finally, they will test the tool in adults receiving palliative care at National Taiwan University Hospital.
Participants in the final stage of the study will be randomly assigned to one of two groups. One group will use NurseChat+ before their scheduled medical visits in addition to receiving usual care, while the other group will receive usual care only. Participants will complete questionnaires about their communication experiences during the study.
調査の概要
詳細な説明
Effective health communication is essential to patient well-being, yet the field is constrained by major theoretical and methodological gaps. Existing theories tend to address isolated communication phenomena and lack an integrative framework spanning the full continuum of patient-provider interaction. As a result, many measurement instruments lack a clear theoretical foundation and demonstrate inconsistent psychometric quality. In parallel, most AI-supported communication tools are technology-driven rather than theory-driven, and few have undergone rigorous clinical evaluation. Palliative care represents a high-stakes clinical context in which communication quality is central to outcomes, making it an ideal setting to test theory-based generative artificial intelligence (GenAI) communication interventions.
Grounded in the Goal-Power Theory of Communication developed by the applicant, this four-year project adopts a mixed-methods design to develop and evaluate a theory-based communication measurement instrument and a GenAI-supported communication aid, NurseChat+. The project comprises three sequential phases: (1) instrument development and validation, (2) intervention development and pilot testing, and (3) clinical evaluation using a randomized controlled trial (RCT). Phase 1 aims to develop and psychometrically validate a theory-based instrument for assessing health communication quality. Instrument development and validation will follow the MEASURE framework, including expert content validation and field testing with approximately 500 participants recruited from clinical settings within the National Taiwan University Hospital system. Phase 2 aims to develop and preliminarily validate the NurseChat+ using a user-centered design approach. A pilot usability and feasibility study will be conducted using a one-group pretest-posttest design with a minimum of 20 healthy adults to assess acceptability, usability, and preliminary effects on communication self-efficacy. Phase 3 will conduct a parallel-group, superiority RCT with an embedded mixed-methods design in palliative care outpatient and home care settings at National Taiwan University Hospital. Eligible adult patients receiving palliative care will be randomly allocated in a 1:1 ratio to the intervention group (NurseChat+ plus usual care) or the control group (usual care alone). The target sample size is 240 participants (120 per group). Intervention participants will use NurseChat+ prior to scheduled medical encounters.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Chia-Chun Tang, PhD
- 電話番号：886-905925300
- メール：chiatang@ntu.edu.tw
研究場所
-
-
-
Taipei、台湾
- National Taiwan University Hospital
-
コンタクト：
- Clinical Trial Center
- 電話番号：886-233668656
- メール：rmcore@ntuh.gov.tw
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Patients (Self-responding)
Inclusion Criteria:
- Age 18 years or older.
- Diagnosed with an advanced disease requiring consultation with outpatient palliative care clinics or home care services.
- Able to self-complete the study questionnaires.
Exclusion Criteria:
-None
Group 2: Caregivers (Proxy-responding) (Invited only when the patient meets the clinical criteria but is unable to self-complete the questionnaires)
Inclusion Criteria:
- Age 18 years or older.
- Identified as the primary family caregiver of a patient with an advanced disease requiring palliative care.
Exclusion Criteria:
- Professional or paid caregivers.
- Unable to complete the study questionnaires.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：他の
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：NurseChat+ plus usual care
Participants in the experimental group will be invited to interact with NurseChat+ on an iPad provided by the research team before beginning their medical consultation.
Successful completion of the intervention is defined as either a minimum of ten minutes of NurseChat+ use or completion of a full round of patient input, data retrieval, and response generation
|
Participants will use NurseChat+, a generative AI-supported communication tool, before scheduled palliative care visits to help prepare questions and concerns for discussion with healthcare providers.
The intervention is provided in addition to usual care.
|
|
介入なし：Usual Care
Participants in the control group will receive usual palliative care without access to the NurseChat+ intervention.
Usual care includes standard clinical consultations and communication with healthcare providers as provided in routine practice.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in Communication Self-Efficacy via the 5-item Perceived Efficacy in Patient-Physician Interaction Scale (PEPPI-5)
時間枠：Baseline (T0: within 12 hours prior to the scheduled consultation) and Post-test (T1: immediately following the medical consultation or the interaction with GenAI communication aid).
|
【Randomized Control Trial & Pilot study】The PEPPI-5 is a 5-item self-report instrument used to measure a patient's perceived self-efficacy in communicating with their physician.
Each item is scored on a 5-point Likert scale from 1 (not at all confident) to 5 (very confident).
The total score ranges from 5 to 25, with higher scores indicating higher levels of communication self-efficacy.
Outcome will be assessed as the change in scores from T0 to T1.
|
Baseline (T0: within 12 hours prior to the scheduled consultation) and Post-test (T1: immediately following the medical consultation or the interaction with GenAI communication aid).
|
|
Quality of Health Communication via the Phase-One Developed Instrument
時間枠：Post-test follow-up (T1: 24-72 hours after the consultation via telephone interview).
|
Evaluated using a newly developed and validated communication-quality instrument generated in Phase One of the study. This instrument is designed to comprehensively assess the specific communication quality, patterns, and clinical encounter effectiveness between healthcare providers and palliative care patients/families when aided by GenAI communication aid. The instrument is currently undergoing development and psychometric validation. The finalized total score will be structured such that higher scores will mathematically indicate a superior quality of health communication and better communication patterns. |
Post-test follow-up (T1: 24-72 hours after the consultation via telephone interview).
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
System Usability Scale (SUS) Score of NurseChat+
時間枠：Post-test (immediately after the interaction with GenAI communication aid).
|
【Pilot study】The UEQ contains 26 pairs of contrasting adjectives used to evaluate the user experience of NurseChat+ across 6 scales (Attractiveness, Perspicuity, Efficiency, Dependability, Stimulation, and Novelty).
Each item is scored on a 7-point scale ranging from -3 (horrible/extremely bad) to +3 (excellent/extremely good).
Scores above 0.8 represent a positive evaluation.
|
Post-test (immediately after the interaction with GenAI communication aid).
|
|
Inventory of Technology Acceptance Model (ITAM) Score
時間枠：Post-test ( immediately after the interaction with GenAI communication aid)
|
【Pilot study】The ITAM assesses user acceptance, perceived usefulness, and perceived ease of use regarding the NurseChat+ GenAI system.
Items are scored on a 7-point Likert scale, ranging from 1(strongly disagree) to 7 (strongly agre), with higher total scores indicating a higher intention to adopt and greater acceptance of the technology.
|
Post-test ( immediately after the interaction with GenAI communication aid)
|
|
Evaluation of User Experience via the User Experience Questionnaire (UEQ)
時間枠：Post-test (immediately after the interaction with GenAI communication aid)
|
【Pilot study】The UEQ is a 26-item semantic differential scale used to provide a holistic assessment of the user experience of NurseChat+. It measures both pragmatic qualities (efficiency, perspicuity, dependability) and hedonic qualities (stimulation, novelty), along with overall attractiveness. Each item consists of a pair of contrasting adjectives rated on a 7-point scale ranging from 1 to 7. For analysis, responses are transformed to range from -3 (horribly bad) to +3 (extremely good), where 0 represents a neutral evaluation. Higher positive values reflect a superior user experience, and scale scores above 0.8 generally indicate a positive evaluation. |
Post-test (immediately after the interaction with GenAI communication aid)
|
|
Improvement in Symptom Burden via the Edmonton Symptom Assessment System (ESAS)
時間枠：Baseline (T0: within 12 hours prior to the scheduled consultation) and Post-test (T1: post-consultation follow-up within 24-72 hours).
|
【Randomized Control Trial】The ESAS is a validated tool designed to assess 9 common symptoms in palliative care patients (pain, tiredness, drowsiness, nausea, appetite, shortness of breath, depression, anxiety, and wellbeing).
Each symptom is rated on a visual analogue scale from 0 (no symptom) to 10 (worst possible symptom).
The total distress score ranges from 0 to 90, with higher scores indicating a higher symptom burden.
|
Baseline (T0: within 12 hours prior to the scheduled consultation) and Post-test (T1: post-consultation follow-up within 24-72 hours).
|
|
Patient Overall and Communication Satisfaction via the Chinese Patients' Satisfaction Scale (C-PSS)
時間枠：Post-test follow-up (T1: 24-72 hours after the consultation via telephone interview).
|
【Randomized Control Trial】The C-PSS is a 27-item instrument validated in Taiwan's outpatient population, assessing 6 dimensions: efficiency, fairness, chin-chieh (kindness), professionalism, responsibility, and respect.
Each item is rated on a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree).
With reverse-scored items appropriately adjusted, total scores are aggregated, where higher total scores indicate greater patient communication and overall satisfaction with the clinical encounter.
|
Post-test follow-up (T1: 24-72 hours after the consultation via telephone interview).
|
|
Patient Satisfaction with Decision Making via the Satisfaction with Decision (SWD) Scale
時間枠：Post-test follow-up (T1: 24-72 hours after the consultation via telephone interview).
|
【Randomized Control Trial】The Chinese version of the SWD is a 6-item questionnaire designed to assess a patient's satisfaction with the healthcare decision-making process and its clinical outcomes.
Each item is rated on a 5-point Likert scale.
Total scores range from 6 to 30, with higher scores indicating a higher degree of satisfaction and agreement with the decisions made during the medical consultation.
|
Post-test follow-up (T1: 24-72 hours after the consultation via telephone interview).
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 202602057RINB
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。